GO
Loading...

CDW Shares Rise on Private Equity Buyout Report

Reuters
Tuesday, 29 May 2007 | 4:56 PM ET

Shares of CDWrose Tuesday following a report that the computer technology retailer may be a takeover target from private equity firms.

Private equity firms are in talks for a buyout of CDW, which has a market capitalization of about $6 billion, The Wall Street Journal said on Tuesday, citing unnamed sources. Madison Dearborn Partners is considered in the lead to buy CDW.

The talks are at a sensitive stage and could fall apart, the paper said, adding that the buyout firm might also face some late competition.

CDW, based in Vernon Hill, Ill., and Madison Dearborn were not immediately available for comment.

CDW, which mainly sells to government agencies and businesses through a Web-based catalog, last month posted a 24.5% rise in first-quarter net income, buoyed by higher sales of notebook computers, storage equipment, software and video-related equipment.

The results came after the company had expanded its distribution capacity, reorganized its sales force and entered a new market -- selling complex computer systems customized for each client -- in a bid to boost sales.

Shares of CDW are only up about 7% this year. However, shares of the company have already climbed about 28% since early March.

CDW competes against companies like Insight Enterprises and Dell.

  Price   Change %Change
4331
---
NSIT
---

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer discusses Micron Technology and how the company gained control over inventory issues. The bears expect the company's history to repeat itself, but Cramer says this time, it feels different.

  • In this excerpt from a live CNBC interview, Warren Buffett explains why it's extremely unusual for a company's directors to vote against executive compensation plans.

  • Mad Money host Jim Cramer says shareholder activism works for every shareholder, and offers his take on the Valeant/Bill Ackman bid to acquire Allergan. The market is better off for these efforts, he says.